knowledge -WSS

knowledge

author：knowledge 2025-09-29 00:38:56 - browse：665

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： South Korea throws huge K

WSS

Why failed clinical trials don’t always spell doom for a new drug

How doctors and nurses shape Google's AI

Wellcome Trust names Røttingen as its new CEO

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Nick Jonas talks about managing diabetes along with his career

Massive project maps cells in human brain in unprecedented detail

focus

knowledge

Wikipedia

The high cost of giving birth even with insurance

South Korea throws huge K

How one medical school became remarkably diverse

How doctors and nurses shape Google's AI

Novavax promises a turnaround & Lilly roils the obesity market

Medicare to cover more brain scans related to Alzheimer’s drugs

Cancer drug shortages should be causing more outrage

Man killed during FBI raid in connection with threats against Biden, other officials

Cancer drug shortages should be causing more outrage

Methadone doses haven’t kept up in the age of fentanyl

knowledge

What to know about Virgin Galactic's 1st mission taking paying customers to space

Why failed clinical trials don’t always spell doom for a new drug

Female surgeons have lower rates of long

How should state employee insurance handle Wegovy?

NIH trials fail to test meaningful long Covid therapies, experts say

What's changing in Medicare's open enrollment this year?

hotspot

leisure time

Wikipedia

entertainment